Nasdaq vktx.

SAN DIEGO, April 7, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Nov 28, 2023 · Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Nov 13, 2023 · SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... So we'll take a look at whether insiders have been buying or selling shares in Viking Therapeutics, Inc. (NASDAQ:VKTX). ... NasdaqCM:VKTX Insider Trading Volume May 13th 2021.

Viking Therapeutics (NASDAQ: VKTX) Viking Therapeutics specializes in metabolic and endocrine illnesses. It has a robust pipeline of medications targeting muscle wasting, type 2 diabetes, hypertriglyceridemia, and other conditions. The biotech company is also working on treatments for metabolic and endocrine disorders.Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.SAN DIEGO, April 11, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.Apr 16, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...

Viking Therapeutics Inc stock price (VKTX) NASDAQ: VKTX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert …Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...Nov 26, 2023 · Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ... Consolidated Research: 2019 Summary Expectations for Ctrip.com International, Anadarko Petroleum, Viking Therapeutics, Bruker, Tech Data, and Sierra Wireless — Fundamental Analysis, Key ...

Discover historical prices for VKTX stock on Yahoo Finance. View daily, weekly or monthly format back to when Viking Therapeutics, Inc. stock was issued.

Fintel reports that on August 8, 2023, Stifel reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 142.45% Upside. As of August 2 ...

Stock Ratings Screener · Free Ratings Newsletter. This page (NASDAQ:VKTX) was last updated on 12/4/2023 by ...LL28. The last time I spoke about Viking Therapeutics, Inc. (NASDAQ:VKTX), I talked about its progress in advancing its drug VK2809 for the treatment of patients with non-alcoholic steatohepatitis ...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Viking Therapeutics, Inc. (NASDAQ: VKTX) is an American biotechnology company that is focused on the development of novel and orally available therapies for the treatment of metabolic and ...

Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...Mar. 28, 2023, 08:37 AM. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of ...Trending Stocks AMZN Amazon.com, Inc. Common Stock $105.11 -0.34 0.32% TSLA Tesla, Inc. Common Stock $164.04 -0.27 0.16% FRC FIRST REPUBLIC …Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) Thursday . Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) Baxter International Inc (NYSE: BAX) (before the market open)Mar. 28, 2023, 08:37 AM. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of ...

Viking Therapeutics (NASDAQ: VKTX) has had a very promising 2023. They announced very good early results for an obesity drug in March. They then quickly used those good results to sell $250 ...

Mar 29, 2023 · Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ... Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. …What happened Shares of Viking Therapeutics (NASDAQ: VKTX) sank 9.8% lower as of 3:37 p.m. EST on Thursday after falling as much as 12.9% earlier in.Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ... Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...Mar. 28, 2023, 08:37 AM. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of ...Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...

21 sept 2023 ... We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate ... There's no doubt that money can be made by owning shares of ...

See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a wider loss of 19 cents per share for the first quarter compared to a loss of 13 cents per share a year ago. Analysts, on average, had estimated a ...What happened. Investors didn't exactly launch a raid on Viking Therapeutics (NASDAQ: VKTX) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news ...SAN DIEGO, May 16, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for VKTX is $33.80, which is $21.97 above than the current price.Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the …

Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...Instagram:https://instagram. barrons rentalinverted yield curve 2023boots and barns near meglaxo smithkline share price May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ... best art to buy for investmentbest mortgage lenders alaska Fintel reports that on August 8, 2023, Stifel reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 142.45% Upside. As of August 2 ... space x stock prices Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, ...In the last 3 months, 9 analysts have offered 12-month price targets for Viking Therapeutics. The company has an average price target of $33.0 with a high of $40.00 and a low of $24.00. Below is a ...